IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission

eLife

Volumn 7, Issue , 2018, Pages

  Klinkhammer, Jonas ^a   Schnepf, Daniel ^a,b   Ye, Liang ^a   Schwaderlapp, Marilena ^a   Gad, Hans Henrik ^c   Hartmann, Rune ^c   Garcin, Dominique ^d   Mahlakõiv, Tanel ^a,f   Staeheli, Peter ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e UNIVERSITY OF FREIBURG   (Germany)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON; ANTIVIRUS AGENT; CYTOKINE; IFNLR1 PROTEIN, MOUSE; INTERFERON RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENE EXPRESSION; GENE EXPRESSION LEVEL; HOUSEKEEPING GENE; HUMAN; INFECTION PREVENTION; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INOCULATION; LUNG HOMOGENATE; LUNG INFECTION; MOUSE; NONHUMAN; SNOUT; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; C57BL MOUSE; DRUG EFFECT; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; METABOLISM; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; RESPIRATORY SYSTEM; TRANSMISSION; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CYTOKINES; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTORS, INTERFERON; RESPIRATORY SYSTEM; VIRUS REPLICATION;

EID: 85051995357     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.33354     Document Type: Article

References (41)

1. Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, Diamond MS, Ivanova Y, Artyomov M, Virgin HW. 2015. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science 347:266–269. DOI: https://doi.org/10.1126/science.1258025, PMID: 25431490
2. Baldridge MT, Lee S, Brown JJ, McAllister N, Urbanek K, Dermody TS, Nice TJ, Virgin HW. 2017. Expression of Ifnlr1 on Intestinal epithelial cells is critical to the antiviral effects of interferon lambda against norovirus and reovirus. Journal of Virology 91:e02079-16. DOI: https://doi.org/10.1128/JVI.02079-16, PMID: 28077655
3. Blazek K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, Doyle S, McCann F, Williams RO, Udalova IA. 2015. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. The Journal of Experimental Medicine 212:845–853. DOI: https://doi.org/10.1084/jem.20140995, PMID: 25941255
4. Bouvier NM. 2015. Animal models for influenza virus transmission studies: a historical perspective. Current Opinion in Virology 13:101–108. DOI: https://doi.org/10.1016/j.coviro.2015.06.002, PMID: 26126082
5. Broggi A, Tan Y, Granucci F, Zanoni I. 2017. IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nature Immunology 18:1084–1093. DOI: https://doi.org/10.1038/ni.3821, PMID: 28846084
6. Cotton M, Innes S, Jaspan H, Madide A, Rabie H. 2008. Management of upper respiratory tract infections in children. South African Family Practice 50:6–12. DOI: https://doi.org/10.1080/20786204.2008.10873685, PMID: 21603094
7. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, Staeheli P, Wack A. 2013. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathogens 9:e1003773. DOI: https://doi.org/10.1371/journal.ppat.1003773, PMID: 24278020
8. Davidson S, Crotta S, McCabe TM, Wack A. 2014. Pathogenic potential of interferon αβ in acute influenza infection. Nature Communications 5:3864. DOI: https://doi.org/10.1038/ncomms4864, PMID: 24844667
9. Davidson S, Maini MK, Wack A. 2015. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. Journal of Interferon & Cytokine Research 35:252–264. DOI: https://doi.org/10.1089/jir.2014. 0227, PMID: 25714109
10. Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R, Wack A. 2016. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Molecular Medicine 8:1099–1112. DOI: https://doi.org/10.15252/emmm.201606413, PMID: 27520969
11. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. 2009. Human interferon-lambda3 is a potent member of the type III interferon family. Genes & Immunity 10:125–131. DOI: https://doi.org/10.1038/gene.2008.87, PMID: 18987645
12. Edenborough KM, Gilbertson BP, Brown LE. 2012. A mouse model for the study of contact-dependent transmission of influenza A virus and the factors that govern transmissibility. Journal of Virology 86:12544– 12551. DOI: https://doi.org/10.1128/JVI.00859-12, PMID: 22951824
13. Espinosa V, Dutta O, McElrath C, Du P, Chang YJ, Cicciarelli B, Pitler A, Whitehead I, Obar JJ, Durbin JE, Kotenko SV, Rivera A. 2017. Type III interferon is a critical regulator of innate antifungal immunity. Science Immunology 2:eaan5357. DOI: https://doi.org/10.1126/sciimmunol.aan5357, PMID: 28986419
14. François-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, Pellegrini S, Uzé G. 2011. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS One 6:e22200. DOI: https://doi.org/10.1371/journal. pone.0022200, PMID: 21779393
15. Fuchs SY. 2013. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. Journal of Interferon & Cytokine Research 33:211–225. DOI: https://doi.org/10.1089/jir.2012.0117, PMID: 23570388
16. Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, Thanos D, Doyle SE, Kotenko SV, Thanopoulou K, Andreakos E. 2017. Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness. Immunity 46:875–890. DOI: https://doi.org/10.1016/j.immuni.2017.04.025, PMID: 28514692
17. Haller O, Staeheli P, Schwemmle M, Kochs G. 2015. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends in Microbiology 23:154–163. DOI: https://doi.org/10.1016/j.tim.2014.12.003, PMID: 25572 883
18. Herfst S, Böhringer M, Karo B, Lawrence P, Lewis NS, Mina MJ, Russell CJ, Steel J, de Swart RL, Menge C. 2017. Drivers of airborne human-to-human pathogen transmission. Current Opinion in Virology 22:22–29. DOI: https://doi.org/10.1016/j.coviro.2016.11.006, PMID: 27918958
19. Horisberger MA, de Staritzky K. 1987. A recombinant human interferon-alpha B/D hybrid with a broad host-range. Journal of General Virology 68 (Pt 3):945–948. DOI: https://doi.org/10.1099/0022-1317-68-3-945, PMID: 3029315
20. Ivinson K, Deliyannis G, McNabb L, Grollo L, Gilbertson B, Jackson D, Brown LE. 2017. Salivary blockade protects the lower respiratory tract of mice from lethal influenza virus infection. Journal of Virology 91:e00624-17. DOI: https://doi.org/10.1128/JVI.00624-17, PMID: 28446669
21. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunology 4:69–77. DOI: https://doi.org/10.1038/ni875, PMID: 12483210
22. Lazear HM, Nice TJ, Diamond MS. 2015. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity 43:15–28. DOI: https://doi.org/10.1016/j.immuni.2015.07.001, PMID: 26200010
23. Lee-Kirsch MA. 2017. The Type I Interferonopathies. Annual Review of Medicine 68:297–315. DOI: https://doi. org/10.1146/annurev-med-050715-104506, PMID: 27813875
24. Lin JD, Feng N, Sen A, Balan M, Tseng HC, McElrath C, Smirnov SV, Peng J, Yasukawa LL, Durbin RK, Durbin JE, Greenberg HB, Kotenko SV. 2016. Distinct roles of Type I and Type III interferons in intestinal immunity to homologous and heterologous rotavirus infections. PLoS Pathogens 12:e1005600. DOI: https://doi.org/10. 1371/journal.ppat.1005600, PMID: 27128797
25. Mahlakõiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. 2015. Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathogens 11:e1004782. DOI: https://doi.org/10.1371/journal.ppat.1004782, PMID: 25849543
26. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. 2011. Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology 53:1171–1180. DOI: https://doi.org/10.1002/hep.24189, PMID: 21480323
27. Meier E, Fäh J, Grob MS, End R, Staeheli P, Haller O. 1988. A family of interferon-induced Mx-related mRNAs encodes cytoplasmic and nuclear proteins in rat cells. Journal of Virology 62:2386–2393. PMID: 3373571
28. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P. 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathogens 4:e1000151. DOI: https://doi.org/10.1371/journal.ppat.1000151, PMID: 18787692
29. Mordstein M, Michiels T, Staeheli P. 2010a. What have we learned from the IL28 receptor knockout mouse? Journal of Interferon & Cytokine Research 30:579–584. DOI: https://doi.org/10.1089/jir.2010.0061, PMID: 2064 9452
30. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, Schwemmle M, Günther S, Drosten C, Michiels T, Staeheli P. 2010b. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. Journal of Virology 84:5670–5677. DOI: https://doi.org/10.1128/JVI.00272-10, PMID: 20335250
31. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, et al. 2014. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. Journal of Hepatology 61:1238–1246. DOI: https://doi.org/10.1016/j.jhep.2014.07.022, PMID: 25064437
32. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, Diamond MS, Virgin HW. 2015. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347:269– 273. DOI: https://doi.org/10.1126/science.1258100, PMID: 25431489
33. Osterhaus A, Abdullah Brooks W, Broberg E, Raina MacIntyre C, Capua I. 2015. Why should influenza be a public health priority? Vaccine 33:7022–7025. DOI: https://doi.org/10.1016/j.vaccine.2015.08.049, PMID: 2631 9062
34. Porritt RA, Hertzog PJ. 2015. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends in Immunology 36:150–160. DOI: https://doi.org/10.1016/j.it.2015.02.002, PMID: 25725583
35. Pott J, Mahlakõiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW. 2011. IFN-lambda determines the intestinal epithelial antiviral host defense. PNAS 108:7944–7949. DOI: https://doi.org/10.1073/pnas.1100552108, PMID: 21518880
36. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunology 4:63–68. DOI: https://doi.org/10.1038/ni873, PMID: 12469119
37. Shiroki K, Ishii T, Aoki T, Kobashi M, Ohka S, Nomoto A. 1995. A new cis-acting element for RNA replication within the 5’ noncoding region of poliovirus type 1 RNA. Journal of Virology 69:6825–6832. PMID: 7474095
38. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathogens 4:e1000017. DOI: https://doi.org/10.1371/journal.ppat.1000017, PMID: 18369468
39. Strähle L, Marq JB, Brini A, Hausmann S, Kolakofsky D, Garcin D. 2007. Activation of the beta interferon promoter by unnatural Sendai virus infection requires RIG-I and is inhibited by viral C proteins. Journal of Virology 81:12227–12237. DOI: https://doi.org/10.1128/JVI.01300-07, PMID: 17804509
40. Trinchieri G. 2010. Type I interferon: friend or foe? The Journal of Experimental Medicine 207:2053–2063. DOI: https://doi.org/10.1084/jem.20101664, PMID: 20837696
41. Wack A, Terczyńska-Dyla E, Hartmann R. 2015. Guarding the frontiers: the biology of type III interferons. Nature Immunology 16:802–809. DOI: https://doi.org/10.1038/ni.3212, PMID: 26194286